Evidence map›Paper›PMID 40637740›Full record

ArticleHaematologica2026

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

Tracy Murphy, Boyang Zhang, Tong Zhang, Ian King, Jose-Mario Capo-Chichi, Vikas Gupta, Dawn Maze, Caroline J McNamara, Mark D Minden, Aaron D Schimmer and 14 more

Abstract readMulticenter StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Tracy MurphyPrincess Margaret Cancer Centre, University Health Network, Toronto, ON.
Boyang ZhangDepartment of Biological Chemistry, School of Medicine, University of California, Irvine (UCI), Irvine, California.
Tong ZhangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON.
Ian KingPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON.
Jose-Mario Capo-ChichiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON.
Vikas GuptaDivision of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1.
Dawn MazePrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1.
Caroline J McNamaraPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1.
Mark D MindenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1.
Aaron D SchimmerPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1.
Andre C SchuhPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1.
Hassan SibaiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1.
Karen W L YeePrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1.
Andrea ArrudaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON.
Zhibin LuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON.
Dina KhalafJuravinski Cancer Centre, Hamilton, ON.
Chantal RockwellThe Ottawa Blood Disease Centre, The Ottawa Hospital, Ottawa, ON.
Brian LeberJuravinski Cancer Centre, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON.
Mitchell SabloffThe Ottawa Blood Disease Centre, The Ottawa Hospital, Ottawa, ON.
Anne TierensPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON.
Tracy L StockleyPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON.
Steven M ChanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1.
Stanley W K NgPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Biological Chemistry, School of Medicine, University of California, Irvine (UCI), Irvine, California. stanlewn@uci.edu.
Jean C Y WangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1. jean.wang@uhn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) patients exhibit diverse molecular and cytogenetic changes with heterogeneous outcomes. The functionally-derived LSC17 gene expression score has demonstrated strong prognostic significance in retrospective analyses of adult and pediatric AML cohorts, where above-median scores are associated with worse outcomes compared to below-median scores in intensively-treated patients. Here we used a laboratory-developed clinically-validated NanoString-based LSC17 assay to test the prognostic value of the LSC17 score in a prospective multicenter study of 276 newly-diagnosed AML patients. Each patient's score was classified as high or low by comparison to a previously-established reference score. In the entire cohort, a high LSC17 score was associated with poor risk features, including advanced age and unfavorable genetic mutations. In the subset of 190 patients treated intensively, a high LSC17 score was associated with lower remission rates (63% vs. 94% after induction; P<0.0001), presence of measurable residual disease (46% vs. 10%; P<0.0001), and shorter overall survival (OS, 606 days vs. not reached; P=0.0004; hazard ratio [HR] =2.16; 95% confidence interval [CI]: 1.39-3.35) and relapse-free survival (RFS, 541 days vs. not reached; P=0.001; HR=1.99; 95% CI: 1.29-3.08). In multivariable analysis considering age, white blood cell count and European LeukemiaNet 2022 risk groups, the LSC17 score remained an independent predictor of RFS and OS. Allogeneic stem cell transplantation improved OS for patients with a high but not a low LSC17 score. This study establishes the real-world value of the LSC17 score as a robust tool for risk assessment in AML and paves the way for its incorporation into routine clinical practice.

Indexed as

Biomarkers, TumorLeukemia, Myeloid, AcuteAdolescentAdultAgedAged, 80 and overChildFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPrognosisProspective StudiesRisk AssessmentRisk FactorsBiomarkers, Tumor

Identifiers

PMID40637740
PMCPMC12951172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.